[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_100":101},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","kilvkulvicls2kskbjq2m4e8h","revision",2,"title","Smith+Nephew 第三季度 2026 年交易报告发布","originalTitle","6-K - SMITH & NEPHEW PLC (0000845982) (Filer)","summary","Smith+Nephew 将于 2026 年 11 月 4 日公布第三季度交易报告。报告包含财务数据及市场表现信息。公司为全球医疗技术企业，年销售额达 62 亿美元。","reason","source",{"_11":90,"_91":92,"_93":94,"_95":57,"_96":97,"_98":99},"links",{"_87":88,"_63":89},"publishedAt","2026-10-08T14:55:42.000Z","discoveredAt","2026-10-08T15:15:20.768Z","timelineAt","category","ai-products","tags",[81,82,83,84,85,86],"stockSymbols",[80],"score",25,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fOX_oGD1cjDE",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","1c9c66dc-c1ef-4215-a815-08b0f619f66f","Smith+Nephew 第三季度交易报告发布",{"_72":73,"_15":74},"zh","

\n\nUNITED STATES

\n\nSECURITIES AND EXCHANGE COMMISSION

\n\nWashington, D.C. 20549

\n\nForm 6-K

\n\nReport of Foreign Private Issuer

\n\nPursuant to Rule 13a-16 or 15d-16 under the

\n\nSecurities Exchange Act of 1934

\nOctober\n08, 2026

\nCommission\nFile Number 001-14978

\n\nSMITH & NEPHEW plc

\n(Registrant’s\nname)

\n\nBuilding 5, Croxley Park, Hatters Lane

\n\nWatford, England, WD18 8YE

\n (Address\nof principal executive office)

\nIndicate\nby check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

\nForm\n20-F ✔\n Form 40-F\n__

\n\nTiming of Smith+Nephew Third Quarter 2026 Trading\nReport

\n\nSmith+Nephew (LSE: SN, NYSE: SNN), the global medical technology\ncompany, will announce its trading report for the third quarter\nended 26 September 2026 on Wednesday 4 November 2026 at 7.00am GMT\n/ 2.00am EST. This will be followed by a conference call for\nfinancial analysts at 12.00pm GMT / 7.00am EST, details of\nwhich will be published on the Smith+Nephew website\nat:\nhttps://www.smith-nephew.com/en/who-we-are/investors

\n\nEnquiries

\n\nInvestors/ Analysts

Emily\nHeaven \n \n \n \n \n +44 (0) 1923 477433

Craig\nBijou \n \n \n \n \n +1 (475) 850 8282

Smith+Nephew

\n\nMedia

Charles\nReynolds \n \n \n \n +44 (0)\n1923 477314

Smith+Nephew

LEI:\n213800ZTMDN8S67S1H61

\n\nAbout Smith+Nephew

\n\nSmith+Nephew is a portfolio medical technology business focused on\nthe repair, regeneration and replacement of soft and hard tissue.\nWe exist to restore people's bodies and their self-belief by using\ntechnology to take the limits off living. We call this purpose\n'Life Unlimited'. Our 17,000 employees deliver this mission every\nday, making a difference to patients' lives through the excellence\nof our product portfolio, and the invention and application of new\ntechnologies across our three global business units of\nOrthopaedics, Sports Medicine & ENT and Advanced Wound\nManagement.

\n\n

\n\nFounded in Hull, UK, in 1856, we now operate in more than 100\ncountries and generated annual sales of $6.2 billion in 2025.\nSmith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).\nThe terms 'Group' and 'Smith+Nephew' are used to refer to Smith\n& Nephew plc and its consolidated subsidiaries, unless the\ncontext requires otherwise.

\n\nFor more information\nabout Smith+Nephew, please visit www.smith-nephew.com and\nfollow us on X, LinkedIn, Instagram or Facebook.

\n\nForward-looking Statements

\n\nThis document may contain forward-looking statements that may or\nmay not prove accurate. For example, statements regarding expected\nrevenue growth and trading profit margins, market trends and our\nproduct pipeline are forward-looking statements. Phrases such as\n\"aim\", \"plan\", \"intend\", \"anticipate\", \"well-placed\", \"believe\",\n\"estimate\", \"expect\", \"target\", \"consider\" and similar expressions\nare generally intended to identify forward-looking statements.\nForward-looking statements involve known and unknown risks,\nuncertainties and other important factors that could cause actual\nresults to differ materially from what is expressed or implied by\nthe statements. For Smith+Nephew, these factors include: conflicts\nin Europe and the Middle East, economic and financial conditions in\nthe markets we serve, especially those affecting healthcare\nproviders, payers and customers; price levels for established and\ninnovative medical devices; developments in medical technology;\nregulatory approvals, reimbursement decisions or other government\nactions; product defects or recalls or other problems with quality\nmanagement systems or failure to comply with related regulations;\nlitigation relating to patent or other claims; legal and financial\ncompliance risks and related investigative, remedial or enforcement\nactions; disruption to our supply chain or operations or those of\nour suppliers; competition for qualified personnel; strategic\nactions, including acquisitions and disposals, our success in\nperforming due diligence, valuing and integrating acquired\nbusinesses; disruption that may result from transactions or other\nchanges we make in our business plans or organisation to adapt to\nmarket developments; relationships with healthcare professionals;\nreliance on information technology and cybersecurity; disruptions\ndue to natural disasters, weather and climate change related\nevents; changes in customer and other stakeholder sustainability\nexpectations; changes in taxation regulations; effects of foreign\nexchange volatility; and numerous other matters that affect us or\nour markets, including those of a political, economic, business,\ncompetitive or reputational nature. Please refer to the documents\nthat Smith+Nephew has filed with the U.S. Securities and Exchange\nCommission under the U.S. Securities Exchange Act of 1934, as\namended, including Smith+Nephew's most recent annual report on Form\n20-F, which is available on the SEC's website at www. sec.gov, for\na discussion of certain of these factors. Any forward-looking\nstatement is based on information available to Smith+Nephew as of\nthe date of the statement. All written or oral forward-looking\nstatements attributable to Smith+Nephew are qualified by this\ncaution. Smith+Nephew does not undertake any obligation to update\nor revise any forward-looking statement to reflect any change in\ncircumstances or in Smith+Nephew's expectations.

\n\n◊ Trademark\nof Smith+Nephew. Certain marks registered in US Patent and\nTrademark Office.

\n\nSIGNATURES

\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf\nby the undersigned, thereunto duly authorized.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n\n	\n\n
\n\n	\n\n	\n \n\nSmith & Nephew plc \n
\n\n	\n\n	\n \n(Registrant) \n
\n\n	\n\n	\n\n
\n\n	\n\n	\n\n
\n \nDate:\nOctober 08, 2026 \n	\n \nBy: \n	\n \n/s/\nHelen Barraclough \n
\n\n	\n\n	\n \nHelen\nBarraclough \n
\n\n	\n\n	\n \nCompany\nSecretary \n

","zhKind","complete","SNN","公司与财报","财报","IPO","退市","停复牌","金融","aihot","/items/kilvkulvicls2kskbjq2m4e8h","https://www.sec.gov/Archives/edgar/data/845982/000165495426008852/0001654954-26-008852-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791676800&sig=72c3b858af523efd","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791676800&sig=7a11775d33e5ce74 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791676800&sig=6814978d6a0138cf 96w","changelogVersion","2026-10-01T08:00"]